Stock GILD GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Gilead Sciences, Inc.

Equities

GILD

US3755581036

Real-time Estimate Cboe BZX
Other stock markets
 16:56:23 02/05/2024 BST 		5-day change 1st Jan Change
65.06 USD -0.68% Intraday chart for Gilead Sciences, Inc. -0.06% -19.48%
05:31pm UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating MT
05-01 Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75 MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Gilead Sciences to Present at Upcoming Investor Conferences
BU
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
BU
Gilead: Q1 Earnings Snapshot
AQ
Gilead Sciences Announces First Quarter 2024 Financial Results
BU
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
BU
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
BU
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
BU
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
AQ
Gilead Sciences Announces Completion of Acquisition of CymaBay
AQ
Gilead Sciences Announces Completion of Acquisition of CymaBay
BU
Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant
BU
Gilead Sciences : Kite Cell Therapy Analyst & Investor Event
PU
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
BU
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
BU
Gilead's Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
AQ
Gilead Sciences, Inc. - New Real-World Data Further Support the Use of Veklury for People Hospitalized With COVID-19
AQ
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
BU
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
BU
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
BU
Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GILD Stock
  4. News Gilead Sciences, Inc.
  5. Press Releases